Skip to content

Bausch + Lomb BLCO Long-term debt, gross

Long-term debt, gross at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
Solventum logo
SolventumSOLV
PBH
Prestige Consumer HealthcarePBH
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's long-term debt, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's long-term debt, gross?
Bausch + Lomb (BLCO) reported long-term debt, gross of $5.09B in Q1 2026.
How has Bausch + Lomb's long-term debt, gross changed year-over-year?
Bausch + Lomb's long-term debt, gross increased by 4.4% year-over-year, from $4.88B to $5.09B.
What is the long-term trend for Bausch + Lomb's long-term debt, gross?
Over 3 years (2022 to 2025), Bausch + Lomb's long-term debt, gross has grown at a 27.1% compound annual growth rate (CAGR), from $2.49B to $5.11B.